


## Thalidomide-5-PEG3-NH<sub>2</sub>

|                    |   |
|--------------------|---|
| Cat. No.:          | HY-138786   |
| CAS No.:           | 2743432-13-3  |
| Molecular Formula: | C <sub>19</sub> H <sub>23</sub> N <sub>3</sub> O <sub>7</sub>                             |
| Molecular Weight:  | 405.4   |
| Target:            | E3 Ligase Ligand-Linker Conjugates  |
| Pathway:           | PROTAC  |
| Storage:           | Please store the product under the recommended conditions in the Certificate of Analysis. |



### BIOLOGICAL ACTIVITY

|                           |  |
|---------------------------|--|
| Description               | Thalidomide-5-PEG3-NH <sub>2</sub> is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology <sup>[1]</sup> .  |
| IC <sub>50</sub> & Target | Cereblon   |
| In Vitro                  | PROTACs contain two different ligands connected by a linker; one is a ligand for an E3 ubiquitin ligase and the other is for the target protein. PROTACs exploit the intracellular ubiquitin-proteasome system to selectively degrade target proteins <sup>[2]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only. |

### REFERENCES

[1]. Sato T, et al. Cereblon-Based Small-Molecule Compounds to Control Neural Stem Cell Proliferation in Regenerative Medicine. *Front Cell Dev Biol.* 2021;9:629326. Published 2021 Mar 11.

[2]. Nalawansa DA, et al. PROTACs: An Emerging Therapeutic Modality in Precision Medicine. *Cell Chem Biol.* 2020;27(8):998-995.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA